These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 25676488)

  • 1. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology is a necessary and informative tool in oncology clinical trials.
    Nagtegaal ID; West NP; van Krieken JH; Quirke P
    J Pathol; 2014 Jan; 232(2):185-9. PubMed ID: 24037805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncology trial design: More accurately and efficiently advancing the field.
    Hohl RJ
    Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
    [No Abstract]   [Full Text] [Related]  

  • 4. N-of-1 trials in oncology.
    Collette L; Tombal B
    Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving evidence developed from population-level experience with targeted agents.
    McClellan MB; Daniel GW; Dickson D; Perlmutter J; Berger DP; Miller V; Nussbaum S; Malin J; Romine MH; Schilsky RL
    Clin Pharmacol Ther; 2015 May; 97(5):478-87. PubMed ID: 25676878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 9. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.
    Leighton JK; Saber H; Reaman G; Pazdur R
    Regul Toxicol Pharmacol; 2016 Aug; 79():142-143. PubMed ID: 26952647
    [No Abstract]   [Full Text] [Related]  

  • 11. Choice of control group in randomised trials of cancer medicine: are we testing trivialities?
    Tao D; Prasad V
    Lancet Oncol; 2018 Sep; 19(9):1150-1152. PubMed ID: 30191836
    [No Abstract]   [Full Text] [Related]  

  • 12. Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
    Markman M
    Cancer Invest; 2005; 23(8):735-40. PubMed ID: 16377592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
    Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Antiretroviral Therapy Initiation in HIV-Associated Malignancy: Is There Enough Evidence to Inform Clinical Guidelines?
    Oseso LN; Chiao EY; Bender Ignacio RA
    J Natl Compr Canc Netw; 2018 Aug; 16(8):927-932. PubMed ID: 30099368
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical practice guidelines for the adverse events in medical oncology].
    Isobe T; Hayashi M; Tsubata Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():45-50. PubMed ID: 25831722
    [No Abstract]   [Full Text] [Related]  

  • 16. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ethics of phase 0 oncology trials.
    Abdoler E; Taylor H; Wendler D
    Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.
    Robinson AG; Booth CM; Eisenhauer EA
    Eur J Cancer; 2014 Sep; 50(13):2303-8. PubMed ID: 24974171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.